Randomized, open label, comparative, multicentric, phase II trial comparing trifluridine/tipiracil + oxaliplatin vs FOLFOX regimen as first-line palliative therapy in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer.
Oxaliplatin in combination with trifluridine/tipiracil or 5-fluorouracile (5-FU) in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer.